The Board of Directors of Aurobindo Pharma have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021
For the quarter ended September 30, 2021 (Q2 FY2022), Aurobindo Pharma's total income was Rs 6038.50 crore, against Rs 6537.19 crore in the corresponding quarter of the previous year (YoY) and Rs 5811.88 crore in the previous quarter (QoQ).
For the quarter ended September 30, 2021(Q2 FY2022), the company's net profit was Rs 696.99 crore, against Rs 807.83 crore in the corresponding quarter of the previous year (YoY) and Rs 769.97 crore in the previous quarter (QoQ).
For the 6 months ended September 30, 2021(Half Year Ended FY 2022), the company's total income was Rs 11643.90 crore, against Rs 12408.22 crore in the previous year (YoY) (Half Year Ended FY 2021).
The net profit was at Rs 1466.96 crore for the 6 months ended September 30, 2021 (Half Year Ended FY 2022), compared to Rs 1590.89 crore in the previous year (YoY) (Half Year Ended FY 2021).